Despite the pandemic, oncology still being the therapeutic area with the highest level of investigation among AseBio’s partners. Up until 72% of the new cancer treatments are developed thanks to biotechnology and the sector became key, considering that the number of diagnostics decreased due the health crisis according to SEOM’s data.
Amadix’ CEO, Rocío Arroyo, points out that COVID-19 emergency had absorbed most of the hospital resources, for this the colorectal screening programs had stopped during the pandemic and hadn’t been taken up yet.
Facing up this situation, the innovative solutions given by the biotech companies became essential to earn back that time.
